Lyme Disease Direct And Indirect Panel
This Lyme disease lab panel combines direct detection and antibody testing to help you interpret exposure, timing, and next steps with your clinician.
This panel bundles multiple biomarker tests in one order—your report explains how results fit together.
This is a Lyme disease lab panel, meaning you are not ordering one single “Lyme number.” You are ordering a bundle that looks for Borrelia burgdorferi (the main bacteria that causes Lyme disease) in two complementary ways: direct detection (looking for the organism’s genetic material) and indirect testing (looking for your immune system’s antibody response). Reading the results well depends on your symptoms, timing since exposure, and your pretest probability—so the goal is a clearer story, not a standalone yes/no label.
Do I need this panel?
You might consider a Lyme Disease Direct And Indirect Panel if you have symptoms that could fit Lyme disease (for example: new joint pain or swelling, facial weakness, nerve pain, headaches, heart palpitations, or persistent fatigue) and you have a plausible exposure history such as time in tick-endemic areas, outdoor work, or a known tick bite.
This panel can also be useful when you are trying to make sense of prior testing. A single positive antibody result can be confusing, especially if you are worried about false positives, cross-reactions, or the idea of “chronic infection.” A combined panel helps you compare direct evidence of organism DNA with the pattern of IgM and IgG antibodies, which often changes with time.
Timing matters. Very early after a tick bite, you may not have detectable antibodies yet, and later on, antibodies can remain positive long after an infection has been treated. If you are deciding when to test or whether to retest, this panel is most helpful when it is paired with a clear symptom timeline.
This panel supports clinician-directed care and shared decision-making. It is not meant to diagnose you in isolation or replace an in-person exam—especially if you have severe symptoms (such as neurologic changes, chest pain, fainting, or a rapidly spreading rash), where urgent evaluation is appropriate.
Methods vary by lab, but this panel typically combines nucleic acid amplification (PCR) for direct detection with immunoassays and/or immunoblot-style confirmation for antibody (IgM/IgG) results.
Lab testing
Order the Lyme Disease Direct And Indirect Panel.
Schedule online, results typically within about a week
Clear reporting and optional clinician context
HSA/FSA eligible where applicable
Get this panel with Vitals Vault
Vitals Vault makes it straightforward to order a Lyme-focused lab panel when you want more than a single screening test. You can use this panel to bring structure to your symptom timeline—especially if you are deciding whether your current symptoms are more consistent with a recent infection, a past exposure, or a different cause entirely.
Because this is a multi-part panel, interpretation is about patterns: whether direct detection is present, whether antibodies suggest recent versus past exposure, and whether the overall picture matches your likelihood of Lyme based on geography, season, and clinical features. If your results feel contradictory or hard to reconcile with your symptoms, PocketMD can help you organize questions for your clinician and decide what follow-up testing (or watchful waiting) makes sense.
If you have had mono (EBV) in the past, frequent viral illnesses, or ongoing inflammation concerns, you may also benefit from pairing this panel with other targeted panels over time—based on how your story evolves rather than chasing single results.
- Designed for pattern-based interpretation across multiple Lyme-related test components
- Useful for discussing pretest probability, timing, and retest strategy with your clinician
- PocketMD support to translate multi-marker results into practical next steps
Key benefits of the Lyme Disease Direct And Indirect Panel
- Combines direct detection and antibody testing so you can compare organism evidence with immune response in one panel.
- Helps you interpret IgM versus IgG patterns in the context of symptom timing and exposure risk.
- Reduces over-reliance on a single positive screening result by emphasizing confirmatory patterns across tests.
- Supports retest decisions when early testing may be negative before antibodies develop.
- Clarifies common confusion around persistent antibodies after past infection or treatment.
- Improves conversations with your clinician by aligning results with pretest probability and clinical features.
- Creates a baseline you can trend if your symptoms change or if follow-up testing is clinically appropriate.
What is the Lyme Disease Direct And Indirect Panel?
The Lyme Disease Direct And Indirect Panel is a bundled set of lab tests that looks for evidence of Lyme disease using two different strategies.
Direct testing aims to detect Borrelia burgdorferi itself—most often by looking for bacterial DNA using PCR (polymerase chain reaction). A direct positive result can be compelling, but sensitivity can be limited because the bacteria may not be present in high amounts in blood at the time of testing.
Indirect testing looks for your immune response to Borrelia. These tests measure antibodies—typically IgM (often associated with earlier immune response) and IgG (often associated with later or past exposure). Many labs use a two-step approach: an initial antibody screen followed by a more specific confirmatory method when the screen is positive or equivocal.
Because each approach has strengths and limitations, the value of a combined panel is in the pattern. For example, a person with a classic erythema migrans rash may not need extensive testing to start treatment, while someone with non-specific symptoms and low exposure risk may need careful interpretation to avoid over-calling a borderline antibody result.
This panel does not prove or disprove every possible tick-borne illness. Ticks can transmit other infections (depending on region), and some symptoms overlap with viral illness, autoimmune disease, thyroid issues, anemia, sleep disorders, and post-infectious syndromes. Your history and exam determine whether additional testing is appropriate.
What do my panel results mean?
Mostly negative or non-reactive results across the panel
If direct detection is negative and antibody tests are non-reactive, Lyme disease is less likely—but it is not ruled out in every situation. Early after exposure, antibodies may not have developed yet, and PCR from blood can be negative even in true infection. This pattern is most reassuring when your exposure risk is low and your symptoms are non-specific. If your pretest probability is higher (for example, a compatible illness after tick exposure in an endemic area), your clinician may consider retesting after an appropriate interval, treating based on clinical findings, or evaluating other diagnoses that better match your symptom pattern.
Results that fit your clinical timing and risk (a coherent pattern)
An “optimal” outcome for decision-making is not a particular number—it is a coherent pattern that matches your story. Examples include: a clearly negative panel when your likelihood of Lyme is low, or a clearly positive antibody pattern with confirmatory testing when your symptoms and exposure timing support Lyme disease. When the pattern is coherent, the next steps are usually clearer: treatment decisions, monitoring symptom response, and avoiding unnecessary repeat testing that can keep old antibodies in the spotlight without changing care.
Positive or reactive findings (especially when multiple components agree)
When several components point in the same direction—such as a reactive screening test with confirmatory IgG (and/or IgM in the right timeframe), or a positive direct detection result alongside supportive serology—the likelihood of Lyme disease increases. The clinical context still matters: IgM can be misleading if it remains positive long after symptom onset, and IgG can stay positive for years after past infection. A “high” pattern across the panel is most meaningful when it aligns with compatible symptoms, exposure risk, and timing, and when confirmatory steps are consistent rather than borderline.
Factors that influence Lyme panel results
Your results can be influenced by timing (too early for antibodies, or long after infection when antibodies persist), antibiotic use before testing, and the fact that Borrelia may not be detectable in blood even when infection is present. Cross-reactivity can occur with some infections and immune conditions, which is why confirmatory testing and pattern-based interpretation matter. Pretest probability is a major driver of how you should read a positive result: in low-risk situations, false positives become more likely; in high-risk situations with compatible symptoms, a negative test does not always end the conversation. If you are immunocompromised, pregnant, or have complex neurologic or cardiac symptoms, your clinician may choose different testing strategies or specimen types.
What’s included in this panel
- 18 KD (IGG) BAND
- 23 KD (IGG) BAND
- 23 KD (IGM) BAND
- 28 KD (IGG) BAND
- 30 KD (IGG) BAND
- 39 KD (IGG) BAND
- 39 KD (IGM) BAND
- 41 KD (IGG) BAND
- 41 KD (IGM) BAND
- 45 KD (IGG) BAND
- 58 KD (IGG) BAND
- 66 KD (IGG) BAND
- 93 KD (IGG) BAND
- Borrelia Species Dna, Ql Real Time Pcr, Misc
- LYME DISEASE AB(IGG),BLOT
- LYME DISEASE AB(IGM),BLOT
Frequently Asked Questions
Do I need to fast for the Lyme Disease Direct And Indirect Panel?
Fasting is usually not required for Lyme antibody testing or Lyme PCR. If you are combining this panel with other labs on the same draw (like lipids or glucose), follow the fasting instructions for those tests.
What is the difference between direct and indirect Lyme testing?
Direct testing looks for Borrelia burgdorferi itself, typically by detecting bacterial DNA with PCR. Indirect testing looks for your immune response by measuring antibodies (IgM and IgG). Direct tests can be specific but may miss infection if there is little bacterial DNA in blood; antibody tests can be informative but depend strongly on timing and can remain positive after past infection.
How do I interpret IgM vs IgG in Lyme testing?
IgM is often associated with earlier immune response, while IgG tends to appear later and can persist for years. The key is whether the IgM/IgG pattern matches your symptom timeline and whether confirmatory testing supports the initial screen. IgM results can be misleading if symptoms have been present for a long time, so your clinician may weigh IgG and the overall pattern more heavily.
Can this panel diagnose “chronic Lyme”?
This panel can provide evidence of exposure and, in some cases, support a diagnosis of active or recent infection when the pattern fits your clinical picture. It does not, by itself, validate every explanation for long-term symptoms, because antibodies can persist after treatment and PCR from blood can be negative even in true infection. If you have persistent symptoms, the most useful next step is often a structured evaluation for alternative or additional causes, using your history, exam, and targeted testing.
When should I retest if my results are negative but I’m still concerned?
If you tested very soon after a suspected tick exposure or symptom onset, your clinician may recommend retesting after enough time has passed for antibodies to develop. The right interval depends on your timeline and symptoms. Retesting is most helpful when it changes decisions—such as clarifying a borderline early result or confirming a new exposure.
Is it better to order a Lyme panel or individual tests separately?
A panel is often easier to interpret because it is designed to show a pattern across direct detection and antibody components, rather than leaving you with a single isolated result. Ordering tests separately can make sense in specific clinical scenarios, but it can also increase confusion if you end up with partial information (for example, a screening test without confirmatory context).
What should I do if one part of the panel is positive and another part is negative?
Mixed results are common and do not automatically mean the test is “wrong.” PCR can be negative even when infection is present, and antibodies can be positive from past exposure. The next step is to interpret the pattern with your symptom timeline, exposure risk, and any prior Lyme testing or treatment history. PocketMD can help you organize the key details to review with your clinician.